---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-010079"
form_type: "8-K"
ticker: "DMAA"
cik: "0002028614"
company_name: "Drugs Made In America Acquisition Corp."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:41:16.220955+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Drugs Made In America Acquisition Corp. closes $200M IPO and $4M private placement

## Summary
- IPO of 20,000,000 units at $10.00 each raises $200,000,000 gross proceeds.
- Sponsor purchased 400,000 private units for $4,000,000; $1,100,000 receivable noted.
- Net proceeds of $201,000,000 deposited into trust account ($10.05 per public share).
- Balance sheet shows $201M in trust, $6M deferred underwriting fees, and shareholders' deficit of $6.6M.
- Going concern warning: working capital deficit of $555,420; company must complete a business combination within 15-21 months or liquidate.

## SEC filing metadata
- accession: 0001213900-25-010079
- form_type: 8-K
- ticker: DMAA
- cik: 0002028614
- company_name: Drugs Made In America Acquisition Corp.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2028614/000121390025010079/0001213900-25-010079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2028614/000121390025010079/ea0229853-8k_drugs.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-010079
- JSON: https://secwatch.observer/filing/0001213900-25-010079.json
- Plain text: https://secwatch.observer/filing/0001213900-25-010079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.